ARTICLE | Clinical News
Fasiglifam: Development discontinued
January 6, 2014 8:00 AM UTC
On Dec. 26, 2013, Takeda said it is discontinuing development of fasiglifam due to concerns about liver safety. The compound was in Phase III testing for Type II diabetes. The pharma said it concluded...